Reports Q1 revenue $0, consensus $1.75M. As of March 31 the Company had cash, cash equivalents, and marketable securities of $157.3M, which the Company believes will be sufficient to fund operations into the second half of 2026. “We continue to execute thoughtfully and diligently on our clinical programs,” said Mark Manfredi, CEO of Ikena. “With the dedication of our hyper-focused team and strong balance sheet, we are well positioned to build value for our shareholders by pursuing the development of novel, targeted therapies for patients.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKNA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue